26th week of 2020 patent applcation highlights part 9 |
Patent application number | Title | Published |
20200197314 | PROTEIN PARTICLE WITH A POORLY WATER-SOLUBLE DRUG ENCAPSULATED THEREIN AND PREPARATION METHOD THEREOF | 2020-06-25 |
20200197315 | ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER | 2020-06-25 |
20200197316 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | 2020-06-25 |
20200197317 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | 2020-06-25 |
20200197318 | MICRO/NANOBUBBLE SOLUTIONS FOR TISSUE PRESERVATION AND GENERATION THEREOF | 2020-06-25 |
20200197319 | NANOPARTICLE, PREPARATION PROCESS AND USES THEREOF | 2020-06-25 |
20200197320 | DRUG CARRIER AND DRUG DELIVERY SYSTEM THEREOF | 2020-06-25 |
20200197321 | Selective RARy Ligand-loaded nanoparticles for manipulation of targeted bone growth | 2020-06-25 |
20200197323 | METHODS FOR SUPPRESSING ACCUMULATION OF REFLUX-INDUCED PROTEIN ADDUCTS | 2020-06-25 |
20200197324 | PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF | 2020-06-25 |
20200197325 | METHODS INVOLVING DOWNREGULATING APOBEC3B | 2020-06-25 |
20200197326 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST AMITRIPTYLINE, FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN | 2020-06-25 |
20200197327 | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer | 2020-06-25 |
20200197328 | SPHINGOSINE KINASE TYPE 1 INHIBITORS AND USES THEREOF | 2020-06-25 |
20200197329 | CANNABINOID AND ANESTHETIC COMPOSITIONS AND METHODS | 2020-06-25 |
20200197330 | BROMHEXINE FOR THE TREATMENT OF PAIN | 2020-06-25 |
20200197331 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | 2020-06-25 |
20200197332 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | 2020-06-25 |
20200197333 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | 2020-06-25 |
20200197334 | Paediatric Compositions For Treating Multiple Sclerosis | 2020-06-25 |
20200197335 | CANCER THERAPEUTIC | 2020-06-25 |
20200197336 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | 2020-06-25 |
20200197337 | INHIBITORS AND THEIR USES | 2020-06-25 |
20200197338 | THERAPEUTIC COMPOSITION OF INTRANASAL LIDOCAINE | 2020-06-25 |
20200197339 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | 2020-06-25 |
20200197340 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | 2020-06-25 |
20200197341 | IMMUNMODULATION FOR PREVENTION OF POOR HEALING OF MUSCULOSKELETAL INJURIES IN COMPROMISED PATIENTS | 2020-06-25 |
20200197342 | A METHOD FOR PRODUCING A POLYPHENOLIC COMPOSITION FROM BARLEY MALT | 2020-06-25 |
20200197343 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION | 2020-06-25 |
20200197344 | THERAPEUTIC USE OF COMPOUNDS | 2020-06-25 |
20200197345 | MEMORY IN SUBJECTS WITH MINI-MENTAL STATE EXAMINATION OF 24-26 | 2020-06-25 |
20200197346 | Protection of Polyunsaturated Fatty Acids from Ruminal Degradation | 2020-06-25 |
20200197347 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | 2020-06-25 |
20200197348 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | 2020-06-25 |
20200197349 | COGNITIVE FUNCTION | 2020-06-25 |
20200197350 | METHODS OF REDUCING APOLIPOPROTEIN C-III | 2020-06-25 |
20200197351 | TRIVALENT AND DIVALENT CATIONS AS ADMINISTRABLE AGENTS FOR INCREASED PROCESSIVITY AND IMPROVED FIDELITY OF REVERSE TRANSCRIPTASE IN TELOMERASE AND IN NUCLEIC ACID POLYMERASES | 2020-06-25 |
20200197352 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | 2020-06-25 |
20200197353 | Cannabinoid-Containing Composition | 2020-06-25 |
20200197354 | METHODS, COMPOSITIONS AND CONTAINERS FOR REDUCING SOLID FORM QUERCETIN DEGRADATION AND 2,4,6-TRIHYDROXYBENZOIC ACID TOXIC BYPRODUCT THEREOF | 2020-06-25 |
20200197355 | METHODS, COMPOSITIONS AND CONTAINERS FOR REDUCING SOLID FORM QUERCETIN DEGRADATION AND 2-(3,4-DIHYDROXYBENZOYLOXY)-4,6-DIHYDROXYBENZOIC ACID TOXIC BYPRODUCTS THEREOF | 2020-06-25 |
20200197356 | Compositions With Ketogenic Agents, Cannabinoids, Plant- Derived Substances And Micronutrients | 2020-06-25 |
20200197357 | COMPOSITIONS AND METHODS OF LIPOPHILIC DRUGS | 2020-06-25 |
20200197358 | CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS | 2020-06-25 |
20200197359 | Cannabinoid and Terpene-Infused Topical Cream | 2020-06-25 |
20200197360 | DISPERSION OF FORMONONETIN SOLID LIPID NANOPARTICLES AND PROCESS FOR ITS PREPARATION | 2020-06-25 |
20200197361 | Ammonia Metabolism Promoter | 2020-06-25 |
20200197362 | Cromolyn Compositions for Treatment of Pulmonary Fibrosis | 2020-06-25 |
20200197363 | COMPOSITIONS AND METHODS TO REGULATE HORMONAL CASCADES IN STRESS DISORDERS | 2020-06-25 |
20200197364 | DIHYDROMYRICETIN NANOPARTICLE FORMULATIONS | 2020-06-25 |
20200197365 | TREATMENT WITH NMDA RECEPTOR MODULATORS | 2020-06-25 |
20200197366 | PHARMACEUTICAL COMPOSITION COMPRISING ELIGLUSTAT | 2020-06-25 |
20200197367 | Melatonin for Preventing and Treating Radiation Cystitis | 2020-06-25 |
20200197368 | METHODS OF IMPROVING CANCER CHEMOTHERAPY | 2020-06-25 |
20200197369 | ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE | 2020-06-25 |
20200197370 | NANOPARTICULATE FORMULATION COMPRISING AN mPGES-1 INHIBITOR | 2020-06-25 |
20200197371 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | 2020-06-25 |
20200197372 | Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound | 2020-06-25 |
20200197373 | Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent | 2020-06-25 |
20200197374 | METHODS FOR TREATING PROTEINOPATHIES | 2020-06-25 |
20200197375 | NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | 2020-06-25 |
20200197376 | THERAPEUTICAL METHODS, FORMULATIONS AND NUTRACEUTICAL FORMULATIONS | 2020-06-25 |
20200197377 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | 2020-06-25 |
20200197378 | COMPOSITION FOR PREVENTING OR TREATING SLEEP DISORDERS | 2020-06-25 |
20200197379 | COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS | 2020-06-25 |
20200197380 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | 2020-06-25 |
20200197381 | Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent | 2020-06-25 |
20200197382 | BACTERIAL EFFLUX PUMP INHIBITORS | 2020-06-25 |
20200197383 | COMPOSITION AND METHOD FOR TREATMENT OF NEUROPHYCHIATRIC DISORDERS | 2020-06-25 |
20200197384 | TREATMENT OF HEPATOCELLULAR CARCINOMA | 2020-06-25 |
20200197385 | THERAPEUTIC AGENT FOR CANCER CONTAINING AXL INHIBITOR AS ACTIVE INGREDIENT | 2020-06-25 |
20200197386 | Aza-Aryl 1H-Pyrazol-yl Benzene Sulfonamides | 2020-06-25 |
20200197387 | METHOD FOR TREATING POST-TRAUMATIC STRESS DISORDER | 2020-06-25 |
20200197388 | TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT | 2020-06-25 |
20200197389 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | 2020-06-25 |
20200197390 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | 2020-06-25 |
20200197391 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | 2020-06-25 |
20200197392 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | 2020-06-25 |
20200197393 | Compounds and Their Use for Reducing Uric Acid Levels | 2020-06-25 |
20200197394 | INHIBITION OF SGK1 IN THE TREATMENT OF HEART CONDITIONS | 2020-06-25 |
20200197395 | METHODS FOR TREATING CYSTIC FIBROSIS | 2020-06-25 |
20200197396 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN AKT INHIBITOR, A TAXANE, AND A PD-L1 INHIBITOR | 2020-06-25 |
20200197397 | TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR | 2020-06-25 |
20200197398 | NETARSUDIL AND LOW-DOSE BRIMONIDINE COMBINATION AND USES THEREOF | 2020-06-25 |
20200197399 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE | 2020-06-25 |
20200197400 | METHODS OF SENSITIZING ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER CELLS TO ENDOCRINE THERAPY | 2020-06-25 |
20200197401 | Salts of the Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1H-Pyrazol-1-YL)-3- Cyclopentylpropanenitrile | 2020-06-25 |
20200197402 | PLATINUM-RESISTANT CANCER TREATMENT | 2020-06-25 |
20200197403 | COMBINATION THERAPY | 2020-06-25 |
20200197404 | EMULSION FORMULATIONS OF APREPITANT | 2020-06-25 |
20200197405 | METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS | 2020-06-25 |
20200197406 | BCL-2 INHIBITORS | 2020-06-25 |
20200197407 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | 2020-06-25 |
20200197408 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | 2020-06-25 |
20200197409 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | 2020-06-25 |
20200197410 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | 2020-06-25 |
20200197411 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | 2020-06-25 |
20200197412 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | 2020-06-25 |
20200197413 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | 2020-06-25 |
20200197414 | TREATMENT OF FIBROSIS USING FXR LIGANDS | 2020-06-25 |